[The importance of flu vaccination during CoViD time]. / L'importanza della vaccinazione anti influenzale ai tempi della CoViD.

In the next months, the risk of coinfection with f lu virus and Sars-CoV-2 is high. Despite the number of studies dealing with the consequences of the interaction between the two viruses, the impact of this coexistence on human health is still uncertain. However, achieving high f lu vaccination coverage would mean avoiding hospital overload due to hospitalizations for f lu complications and facilitating a timely differential diagnosis that allows a quick and appropriate treatment of CoViD-19 cases. These are two valid reasons for actively promoting f lu vaccination, particularly this year when the risk of a "twindemic" determined by f lu and CoViD-19 is high. In Italy this year, for the first time, f lu vaccination is offered free of charge also to people aged 60 to 64, expanding individuals entitled to free vaccination. Furthermore, it is strongly recommended to healthcare workers and to elderly who live in residential or long-term care facilities.

[Routine vaccinations during SARS-CoV-2 epidemics]. / Le vaccinazioni di routine ai tempi del SARS-CoV-2.

The circulation of SARS-CoV-2 required the deplacement of resources from routine preventive activities to pandemic-related interventions. The vaccination services have been adapted to the individual territorial realities on the basis of virus circulation and restrictive measures put in place. The reduction of coverage with the consequent accumulation of susceptible subjects increases the risk of vaccine-preventable diseases' epidemics. Catch-up programs and strategies to optimize sessions, such as carrying out co-administrations, are in place on the national territory in order to reduce the risk.

[Vaccines: from the identification of the microorganism to marketing. How long does it take?] / Vaccini: dall'identificazione del microrganismo alla commercializzazione. Quanto tempo ci vuole?

The development of a vaccine, particularly one that can help against the recent pandemic, is a topic that has recently attracted public opinion. More than ninety vaccines are currently being developed against Sars-Cov2 by universities and companies around the world. They are protein-based vaccines, viral vector vaccines, DNA or RNA vaccines and inactivated or attenuated viral vaccines. The development of a vaccine starts from the identification and characterization of the microorganism that causes the disease. The second step is the preclinical phase. Then, there is the phase of clinical experimentation, which allows to study the posology, efficacy and safety of the vaccine, on an increasingly larger sample. In the European Union, vaccines are authorized through two procedures (EU and national) based on the quality, safety and efficacy requirements defined by the European and international guidelines. Timing of realization, authorization and marketing of new vaccines can be shortened in cases of particular need, through an accelerated evaluation known as "Priority Medicines". In this period, it is crucial not to neglect current vaccinations. In fact, during the pandemic period, many countries postponed vaccination campaigns against many vaccine-preventable diseases, causing a marked decrease in routine immunizations in childhood.

[Tuberculosis: an ever present disease but difficult to prevent]. / Tubercolosi patologia sempre attuale e difficile da prevenire.

Tuberculosis (TB) is an infectious and contagious disease caused by Mycobacterium tuberculosis, commonly called Koch's bacillus. TB is spread by air and is present all over the world. Not everyone who become infected develop the disease; the immune system can cope with the infection and the bacterium can remain dormant for years. Despite advances in therapy and prevention, TB remains one of the top 10 causes of death worldwide. Over 9 million new cases and over 1 million deaths occur each year. Since 1921 BCG has been the only authorized vaccine. More than ten experimental vaccines are currently in different stages of development. Depending on the type, they are divided into vaccines consisting of: live attenuated, inactivated mycobacteria and subunits. According to their purpose they can be divided in: vaccines aimed at preventing infection, vaccines aimed at preventing disease, vaccines aimed at preventing recurrence and therapeutic vaccines. Hopefully, these numerous attempts to develop new vaccination approaches will lead to obtain products with greater immunogenicity and efficacy.

[Old outbreaks and new vaccines: Italy facing Ebola]. / Vecchie epidemie e nuovi vaccini: l'Italia di fronte al problema Ebola.

Zaire is the name of the most deadly Ebola Virus (ZEBOV), which caused many outbreaks in past years and is the causative agent of the most recent one. In July 2019, Ebola was declared a public health emergency of international concern. After this declaration, the steps required to prequalify and approve the r VSV ZEBOV vaccine followed each other quickly. Nowadays in Europe the risk of an outbreak is low. However, secondary cases in USA and Spain have alerted public opinion. Italy is not involved except for the assistance to its citizens infected in countries at risk mainly in contexts of humanitarian aid. In epidemic areas the situation deserves close monitoring, as shown by the interest of the WHO, FDA and EMA. Last year the Italian Ministry of Health issued four circulars on this subject to update epidemic data and procedures and to remember precautions. The live attenuated vaccine in use now shows encouraging results; however, the need to evaluate further vaccines remains to guarantee efficacy, safety and adequate quantities.

[Anti-flu Vaccine: tailor made solutions in large-scale distribution]. / Vaccino anti-influenzale: scelte sartoriali nella grande distribuzione.

Influenza is a public health problem with a strong impact from an epidemiological, clinical and economic point of view. Many factors contribute: ubiquity and contagiousness of the disease, antigenic variability of the viruses and the possibility of serious complications. Influenza rarely causes complications in healthy subjects. On the contrary complications can occur and be severe in people with fragile conditions. More susceptible to infection are: children, elderly, pregnant women, people with chronic conditions or undergoing immunosuppressive therapies. Vaccine is an important preventive measure. It allows to protect both the vaccinated person and those at risk. Thanks to the presence of diversified vaccines, we can offer targeted prevention. Vaccine innovations also involved production methods, allowing GPs to choose a quadrivalent cell-derived in addition to the quadrivalent egg-derived and the trivalent vaccine. Age, existing pathologies and immune system reactivity are fundamental elements guiding the customized choice of GPs. Recent years innovations concerning the increased immunogenicity (adjuvated and high-dose vaccines) and the protection against a greater number of strains (quadrivalent vaccine) in addition to new production methods (cell derived vaccine) allow us to trust in further possibilities for the future.

[Anti-pneumococcus, anti-herpes-zoster and anti-papillomavirus vaccinations: experience in programming continuing education courses in local health units in Rome]. / Vaccinazioni anti-pneumococco, anti-herpes-zoster e anti­ papillomavirus: esperienza nella programmazione di corsi di formazione nelle asl di Roma.

The National Vaccine Prevention Plan considers the recommendations for immune prophylaxis in all ages of life. However, compulsory vaccination introduced in 2017 focused the attention on improving global vaccination coverage in infants and children, giving less attention to adult/elderly vaccinations. The immunization of this population is necessary considering the change in the age structure of the population, whose average life expectancy is increasing. Aim of this work was the organization of continuing education courses about anti-Pneumococcus, anti-Herpes-Zoster and anti-Papillomavirus vaccinations to offer an update of knowledge and to discuss the attitudes of health professionals in vaccination centers of the Local Health Units in Rome.

[Adverse reactions after repeated doses of anti-tetanus vaccine: scientific evidences]. / Reazioni avverse dopo dosi ravvicinate di vaccino anti-tetanico nell'adulto: una ricerca sulle evidenze scientifiche.

The possible risk of hyperimmunization after tetanus vaccination is currently discussed after the National Vaccine Prevention Plan 2017-2019 confirmed the recommendation of a booster dose every ten years. Due to the ubiquitous nature of tetanus spores and the inability to obtain herd-immunity through vaccination, efforts to reduce the incidence of tetanus aim at eliminating the disease. The only way to prevent infection is vaccination followed by recommended periodic booster doses. Between 2012 and 2016, Italy notified 45% (252/564) of all cases reported by the 26 EU Member States, most of them in the over 65 age group, generally women in the rural areas. The recommendation of the antipertussis vaccine, combined with anti-tetanus, in pregnancy and the indications for antitetanic prophylaxis by vaccination or specific immunoglobulins in emergency setting, gives rise to doubts about the risk of hyperimmunization. Studies generally agree on the safety of diphtheria-tetanus-pertussis combined vaccines during the third trimester of pregnancy, and the time elapsed since the previous tetanus vaccination seems not to be related to significant differences in the incidence of adverse events or obstetrical complications. In the emergency wards, given the relatively high incidence of tetanus in Italy, the risk/benefit ratio often leads to prefer vaccination to no-intervention. The administration of tetanus immunoglobulins in subjects not vaccinated in the last 10 years seems justified by the epidemiology of tetanus in Italy.

Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies.

Population aging is a worldwide phenomenon with significant and manifold impacts on society. Advanced age correlates with the onset of frailty. In this vulnerable state, the immune response is weakened and a higher susceptibility to infectious diseases is observed. The present narrative review aims to cover the topic of herpes zoster (HZ) and its complications in frail populations. The lifetime risk of developing HZ is estimated at about 20-30%, and the risk increases with age. In older people, HZ can lead to the inability to recover the lifestyle, the interests, and the level of activity that existed before its development. Severity of the disease at presentation and depression are the major correlates of pain burden in patients with acute HZ and postherpetic neuralgia (PHN). The frail elderly need careful assessment prior to treatment initiation and could be affected to a greater extent by treatment-related adverse events. In light of the significant burden caused by HZ and its complications in the frail elderly, the adoption of a preventive strategy appears to be promising, particularly using vaccination in appropriate age- and risk-groups. Although very few vaccine studies consider explicitly the frail elderly as their study population, there is evidence that the live, attenuated vaccine induces significant immunological responses. An adjuvanted recombinant subunit vaccine has recently been approved in Canada, in the United States, in the European Union, and in Japan, and will likely provide additional opportunities for prevention.

[Epidemics of Hepatitis A and opportunities for vaccination: a focus on the category of men who practice sex with men (MSM)]. / Epidemie di Epatite A e opportunità della vaccinazione: un focus sulla categoria degli uomini che praticano sesso con uomini (MSM).

Hepatitis A is an infectious disease caused by a virus (HAV), which is highly contagious and widespread all over the world. In industrialized countries, Hepatitis A is commonly considered a disease with an important socio-economic impact, as the clinical disease affects mostly young adults. After the development of a specific anti-HAV vaccine, a reduction in the incidence of Hepatitis A was observed, with a subsequent change in the prevalence of HAV. HAV spreads mainly in children and risk categories, whose work or activities or medical conditions lead to a close contact with the virus. In particular, in Men who have sex with Men (MSM) many outbreaks have been reported in the last five years. Aim of this paper is an evaluation of the recent literature about HAV infection in MSM in order to update the current guidelines on HAV procedures for MSM.

[Vaccines and sport: risk perception among athletes]. / I vaccini in ambito sportivo: percezione del rischio tra gli atleti.

Infection prevention is a key issue in both general population and in categories at risk, among which the athletes. There are risk factors related to the sporting practice performed at every level, from the amateur to the elite athletes. The control of the vaccination schedule and the empowerment of the sportsman in this area should be carried out both by the General Practitioner or the Pediatrician and by the federations to which the athletes belong. There is a need for guidelines and it is necessary to inform the athletes. This study was performed to evaluate the attitude of groups of athletes regarding infectious diseases and vaccination and confirms the lack of attention towards immunization in sports. Protocols for sport medical examinations, indeed, do not require controls on the state of vaccination and the offer of specific vaccines. It is therefore important the role that scientific societies are taking on in recommending immune prophylaxis for sportsmen.

[Prevention of vector-borne diseases in Italy]. / Prevenzione delle Infezioni trasmesse da vettori in Italia.

In recent years, a constant increase of vector-borne diseases has been seen in Italy, due to various conditions including climate change, trade and international travel. These factors contribute to the diffusion on the Italian territory of newly introduced carriers and pathogens. These new pathogens can be an emerging cause of epidemics, as in the case of the Chikungunya virus in 2007 and in 2017, or can establish a true endemic disease, as in the case of the West Nile virus. It is even possible that diseases that had been endemic in the past, which were subsequently eliminated in Italy, could be reintroduced, as in the case of malaria. This review aims to illustrate the recent evolution of the diffusion of vectors and of the pathogens they convey, and to investigate which emerging pathogens could be responsible in the immediate future for new epidemics / endemics in Italy. Nowadays it is necessary to keep those neglected emerging diseases in mind, in order to establish a correct diagnostic-therapeutic approach at the individual level, and to identify the measures to avoid their diffusion at the community level. Preventive interventions, such as available vaccines or individual protection from vectors, are also discussed.

[Influenza prevention in health-care workers: enhancement of the influenza vaccination campaign at Policlinico Tor Vergata in Rome (Italy) during the 2017/2018 epidemic season]. / La prevenzione dell'influenza negli operatori sanitari: campagna vaccinale presso il policlinico Tor Vergata di Roma nella stagione 2017/2018.

Given the very low influenza vaccination coverage averaging 4% among health-care workers at Policlinico Tor Vergata during the previous epidemic seasons, it was decided to implement a series of interventions to promote influenza vaccination compliance in the current (2017/2018) season. The total number of vaccinated health-care workers at the end of the current season was 364, resulting in a vaccination coverage of approximately 12%. The increase took place in all professional groups, with a coverage of 25% among permanent MDs, 9% among Medical Residents, 3% among nurses and 8% among technicians. The influenza vaccination coverage of 12%, although very low compared to the minimum target of 75%, is broadly in line with the values reported by other hospitals in Italy.

[Vaccine co-administration in clinical practice]. / Somministrazione contemporanea dei vaccini nella pratica clinica.

Vaccines are biological products designed to induce a protective immune response, mimicking natural infection without the development of disease and / or complications. Combined vaccine administration and vaccines co-administration is a safe and effective practice, the benefits of which outweigh the disadvantages. The operators should assess individual variations for the completion of the vaccination schedule, which may be necessary in clinical practice, case by case. Often there are myths to dispel, such as fears about the overload of the immune system, the remora to do more injections in the same session, excessive reactogenicity and some false contraindications. The operators, in order to resolve their doubt in performing non-routine co-administrations, can rely on the Summary of Product Characteristics (SPC) of the individual vaccines and on the new available evidence.

[Vaccines: benefits have been forgotten]. / Vaccini, dimenticati i perché a loro favore.

The increased use of vaccination has led to a significant decrease or even to the disappearance of serious infectious diseases. Currently, vaccines are often evaluated by their potential side effects while ignoring the benefits. This happens because of memory loss. The memory of the damage caused by vaccine-preventable diseases has been lost. This paper illustrates the epidemiology of the major vaccine-preventable diseases and the risk of reintroduction of many pathologies in case the vaccine coverage continues to decrease.

[Bacterial lysates: history and availability]. / Storia e diffusione dei lisati batterici utilizzati come "vaccini".

The use of bacterial lysates (BLs) can be traced back to the end of the nineteenth century, and they are currently available in several countries across all continents. Over the last few decades, BLs have been used, both in pediatric patients and in adults, mainly for the prevention and treatment of bacterial infections of the respiratory tract. BLs are produced from bacterial cultures that undergo cell lysis with two different methods: mechanical lysis and chemical lysis. The in vivo mechanism of action is still not fully understood, and the main hypotheses focus on mucosal immunity modulation. We searched PubMed for relevant papers on the use of BLs for the prevention and treatment of chronic obstructive pulmonary disease and recurrent respiratory infections both in adult and in pediatric patients. We retrieved 169 articles and after screening and selection, we analyzed 13 RCTs focusing on adult patients and 8 on pediatric patients. The outcomes assessed were mainly about the efficacy of BLs on exacerbations, hospitalizations, antibiotic treatment, fever, number of episodes and days of absence from work or school. Many aspects of BLs are still not well understood and the quality of available studies is not satisfactory; in order to place BLs within the scope of Public Health, further good quality studies are needed, keeping in mind the necessity to respond to the needs of patients for whom no alternative effective treatments are available.

[Recall system for vaccinations in preschool children in a Local Health Unit in Rome, Italy]. / Recupero dei richiami vaccinali dell'età prescolare in un distretto della ASL Roma 2.

In Italy, in this period, much attention is dedicated to reach adequate vaccination coverage in children and adolescents. In this study, Vaccination Registry was checked in a Local Health Unit in Rome, Italy, to identify children born in 2007 and 2008 who had not completed the vaccination schedule. Coverage for booster doses of measles, mumps, rubella and for diphtheria, tetanus, pertussis and polio vaccines in the 2213 children was around 70%. A reminder letter was send to parents of the 661 incompletely immunized children and, if they did not reply, a phone call was made when the phone number was available. With this recall system, 12% of the children were correctly immunized, reaching about 82% coverage.

[The Italian Immunization Plan 2017: analysis and starting point for the Regional Plans]. / Il nuovo Piano Nazionale Prevenzione Vaccinale 2017-2019: analisi e punto di partenza per i piani regionali.

The National Immunization Plan 2017-2019 has been approved on January 2017. This official document contains the new Italian guidelines to improve vaccination coverage in the country. We conducted an accurate and critical analysis of the document, highlighting its key points and critical issues, in order to offer an practical tool for writing the Regional Plans. The new immunization schedule and the establishment of a restricted panel for the vaccine vigilance are the most significant innovations of the Plan. The Plan addresses also the issues of mandatory vaccination and of penalties for physicians who advise against vaccinations. Together with the presence of qualifying aspects as information about the ethical value and the benefits of vaccination, the Plan contains other interesting proposals, such as the introduction of a computerized vaccination register and the targeted use of new technologies to reach the population extensively. The Plan is set up as a conceptually rich tool, suitable for the development of regional operational plans.

[HPV vaccination: active offer in an Italian region]. / Offerta attiva della vaccinazione anti-HPV nella Regione Lazio.

Human Papillomavirus is responsible for 4.8% of cancers, and is the main cause of cervical cancer. Cervical cancer can be reduced by mean of secondary prevention (PAP-test, HPV-DNA test), while through primary prevention (anti-HPV vaccine) the incidence of other HPV-attributable cancers can also be reduced. In Italy, anti-HPV vaccination is part of the immunization schedule in girls since 2008, and in 2017 it was extended to boys. However, vaccine coverage is decreasing nationwide. This study aims to examine anti-HPV vaccination practices in Health care services of Lazio Region, Italy. Questionnaires were sent or administered directly to those in charge of vaccinations. Data, collected from 11/12 (92%) Lazio Local Health Units and from 116 vaccination centers, show a remarkable diversity in the offer: 41% of the centers open only 1-2 days/week, 42% only in the morning, and only 7% are open on Saturday. Vaccination is available by reservation only in 62% of the centers, while vaccines are not administered to ≥18 years subjects in 33%; 93% of the centers call actively the girls in the target cohort, while 70% and 94% recall the patients who had not received the first or the second dose of vaccine, respectively. Collaboration with family physicians and/or pediatricians was declared by 80% of the centers. Vaccine coverage could probably be improved by addressing the highlighted critical issues and applying best practices widely.

[Vaccines for the treatment of drug addiction]. / Vaccini contro la dipendenza da sostanze psicoattive.

The treatment of drug addiction is a very wide-ranging sector within modern medicine. The use of immunotherapy in this context represents an innovative approach. The purpose of this paper is to illustrate, through a literature review, the main avenues of research and the results obtained with immunotherapy in the treatment of drug addiction.